Rostislav Christov Raykov Sells 9,747 Shares of Fennec Pharmaceuticals (TSE:FRX) Stock

Fennec Pharmaceuticals Inc. (TSE:FRX) Director Rostislav Christov Raykov sold 9,747 shares of Fennec Pharmaceuticals stock in a transaction dated Monday, June 1st. The stock was sold at an average price of C$13.23, for a total value of C$128,952.81. Following the completion of the transaction, the director directly owned 2,746,104 shares of the company’s stock, valued at approximately C$36,330,955.92. This trade represents a 0.35% decrease in their ownership of the stock.

Rostislav Christov Raykov also recently made the following trade(s):

• On Monday, June 1st, Rostislav Christov Raykov bought 15,597 shares of Fennec Pharmaceuticals stock. The stock was purchased at an average cost of C$3.37 per share, with a total value of C$52,561.89.

Fennec Pharmaceuticals Stock Performance

Shares of TSE FRX remained flat at C$12.72 during mid-day trading on Thursday. 1,030 shares of the stock were exchanged, compared to its average volume of 1,286. The business has a fifty day moving average of C$10.30 and a 200-day moving average of C$10.62. The company has a market capitalization of C$441.85 million, a PE ratio of -43.86 and a beta of 3.52. Fennec Pharmaceuticals Inc. has a 52-week low of C$7.59 and a 52-week high of C$14.24.

Analyst Upgrades and Downgrades

Separately, B. Riley Financial raised Fennec Pharmaceuticals to a “strong-buy” rating in a report on Wednesday, February 11th. One investment analyst has rated the stock with a Strong Buy rating, According to data from MarketBeat.com, the stock presently has a consensus rating of “Strong Buy”.

Fennec Pharmaceuticals Company Profile

Fennec Pharmaceuticals Inc is a specialty pharmaceutical company committed to the fight against ototoxicity in cancer patients who receive cisplatin-based chemotherapy. Fennec is focused on the commercialization of PEDMARK® to reduce the risk of platinum-induced ototoxicity in cancer patients. PEDMARK received FDA approval in September 2022 and European Commission approval in June 2023 and United Kingdom ( U.K. ) approval in October 2023 under the brand name PEDMARQSI®. In March 2024, Fennec entered into an exclusive licensing agreement under which Norgine Pharmaceuticals Ltd., a leading European specialist pharmaceutical company, with rights to commercialize PEDMARQSI® in Europe, U.K., Australia and New Zealand.